MedTrace Logo

To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

NCT05483907 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2025-04-01

No results posted yet for this study

Summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).

Conditions

Interventions

DRUG

BBT-877

BBT-877 24 weeks + Follow-up 4 weeks

DRUG

Placebo

Placebo 24 weeks + Follow-up 4 weeks

Sponsors & Collaborators

  • Bridge Biotherapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-12
Primary Completion
2025-01-26
Completion
2025-02-23
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Israel
  • Poland
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05483907 on ClinicalTrials.gov